From: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses
Adverse effect | Included outcomes | ||
---|---|---|---|
 | Death | Persistent disability | Life-threatening reaction |
Acute severe allergy | Yes | No | Yes |
Cardio-pulmonary distress | Yes | Yes | Yes |
Diabetes | Yes | Yes | Yes |
Gastrointestinal haemorrhage | Yes | Yes | Yes |
Hepatotoxicity | Yes | Yes | Yes |
Myopathy | No | Yes | Yes |
Osteonecrosis | No | Yes | No |
Pancreatitis | Yes | No | No |
Psychosis | No | Yes | Yes |
Seizure | Yes | Yes | Yes |
Ventricular arrhythmia/cardiac arrest | Yes | Yes | Yes |